📅 29 June 2026 | EarnFree.in | India AI & Tech Stocks
Three standout positive stories on June 29 from India’s technology and pharma space — all AI-related. Hexaware jumped 8% after being named an Anthropic Authorized Reseller for Amazon Bedrock, joining a select global group able to sell Claude AI models directly to enterprise clients. HCLTech completed its 10.46% stake purchase in Sarvam AI — India’s leading multilingual AI startup. And Dr Reddy’s surged 4.4% after USFDA cleared its Bachupally biologics plant for pre-licensing — a massive unlock for India’s biologics export potential.
🤖 Hexaware + Anthropic = Claude AI for Indian Enterprise
Hexaware Technologies (NSE: HEXAWARE) has been named an Anthropic Authorized Reseller for Amazon Bedrock — meaning it can now sell, integrate, and support Claude AI models directly to enterprise customers worldwide. Claude’s safety-first architecture makes it particularly suited to regulated industries like banking, insurance, and healthcare — exactly where Hexaware has deep delivery capabilities. Siddharth Dhar, Hexaware’s President of AI: “This authorization underscores the strength of our foundational AI capabilities and the confidence our clients have in us.” Hexaware shares rose 8% to ₹534.25 from ₹494.55. The stock is still down significantly from its ₹745.50 listing price — suggesting further recovery runway as AI revenue materialises.
🇮🇳 HCLTech + Sarvam AI — Hindi AI at Scale
HCLTech completed the purchase of a 10.46% equity stake in Sarvam AI — the leading Indian startup building large language models in Hindi and 10+ Indian vernacular languages. Sarvam AI has backing from Lightspeed and Peak XV (Sequoia India). For HCLTech, this bet signals that the next wave of enterprise AI in India will not be in English — it will be in Bhojpuri, Tamil, Bengali, and Kannada. HCLTech gets early access to Sarvam’s models for deploying vernacular AI in its BPS and enterprise software clients.
💊 Dr Reddy’s +4.4% — USFDA Biologics Plant Cleared
Dr Reddy’s Laboratories (NSE: DRREDDY) surged 4.4% after the USFDA completed a pre-licensing inspection of its Bachupally, Hyderabad biologics manufacturing plant with no critical observations. This is a major milestone — it means Dr Reddy’s biologics products from this plant are eligible for US market approval. India’s biologics export market is projected at $10 billion by 2030. Dr Reddy’s biosimilar pipeline includes products targeting oncology, diabetes, and autoimmune conditions — markets where US biosimilar adoption is accelerating under the Inflation Reduction Act.
🎯 India AI Stock Picks — June 29, 2026
| Stock | Today | Catalyst | View |
|---|---|---|---|
| Hexaware (HEXAWARE) | +8% ₹534 | Anthropic Bedrock reseller | 🟢 AI revenue incoming — accumulate on dips |
| Dr Reddy’s (DRREDDY) | +4.4% | USFDA biologics clearance | 🟢 US biosimilar pipeline unlocked |
| HCLTech (HCLTECH) | Neutral today | Sarvam AI 10.46% stake | 🟡 Long-term vernacular AI play |
⚠️ Disclaimer: This article is for informational and educational purposes only. This is not SEBI-registered investment advice. Stock prices are subject to market risk. Always consult a certified financial advisor before investing.
